石打穿合剂联合化疗在中晚期食管鳞癌中的应用价值及对患者行为能力的影响  

Application value of Shidachuan Mixture combined with chemotherapy and its effects on KPS behavioral ability in patients with middle and advanced esophageal squamous cell carcinoma

作　　者：张文君 孙长岗[3] ZHANG Wen-jun;SUN Chang-gang(Qingdao University,Qingdao 266071;Changle County Maternal and Child Health Hospital,Weifang 262400;Weifang Hospital ofTCM,Weifang 261041)

机构地区：[1]青岛大学,山东青岛266071 [2]山东省潍坊市昌乐县妇幼保健院,山东潍坊262400 [3]山东省潍坊市中医院,山东潍坊261041

出　　处：《湖北中医药大学学报》2024年第2期18-22,共5页Journal of Hubei University of Chinese Medicine

基　　金：山东省潍坊市科技发展计划项目(医学类)(项目编号:2020YX105)。

摘　　要：目的 观察石打穿合剂联合化疗在中晚期食管鳞癌中的应用价值及对患者KPS行为能力的影响。方法 将我院120例中晚期食管鳞癌患者随机分为研究组与对照组各60例。对照组采用常规化疗方案(紫杉醇+顺铂)治疗,研究组在对照组治疗基础上予石打穿合剂。对比两组治疗后临床疗效,肿瘤标记物鳞状细胞癌抗原(SCC-Ag)、癌胚抗原(CEA)水平、细胞角蛋白-19可溶性片段(CYFRA21-1),炎性因子白细胞介素-2(IL-2)、肿瘤坏死因子-α(TNF-α)、转化生长因子-β(TGF-β)水平,中医症候积分、卡氏行为能力状况量表(KPS)评分、肿瘤患者生活质量评定表(QOL)评分变化及不良反应发生率。结果 治疗后,研究组治疗总有效率、临床控制率均显著高于对照组(P<0.05);两组SCC-Ag、CEA、CYFRA21-1、IL-2、TNF-α、TGF-β水平低于治疗前,研究组SCC-Ag、CEA、CYFRA21-1、IL-2、TNF-α、TGF-β水平均低于对照组(P<0.05);两组各项中医症候积分低于治疗前,研究组各项中医症候积分低于对照组(P<0.05);两组KPS、QOL评分高于治疗前,研究组KPS、QOL评分高于对照组(P<0.05);研究组不良反应发生率低于对照组(P<0.05)。结论 石打穿合剂联合化疗治疗中晚期食管鳞癌患者疗效显著,能有效降低肿瘤标志物及炎性因子水平,改善中医症状,提高患者行为能力及生活质量,减少不良反应发生。Objective To observe the application value of Shidachuan Mixture combined with chemotherapy and its effects on KPS behavioral ability in patients with middle and advanced esophageal squamous cell carcinoma(ESCC).Methods A total of 120 patients with middle and advanced ESCC were randomly divided into study group and control group,60 cases in each group.Control group was treated with routine chemotherapy(paclitaxel+cisplatin),while study group was additionally treated with Shidachuan Mixture.The clinical curative effect after treatment,changes in levels of tumor markers squamous cell carcinoma antigen(SCC-Ag),carcinoembryonic antigen(CEA),cytokeratin-19 soluble fragment(CYFRA21-1),and infla-mmatory factors interleukin-2(IL-2),tumor necrosis factor-α(TNF-α),transforming growth factor-β(TGF-β),TCM syndrome scores,Karnofsky Performance Assessment Scale(KPS)scores,Quality of Life Scale for tumor patients(QoL)scores,and the incidence of adverse reactions were compared between the two groups.Results After treatment,the total response rate of treatment and clinical control rate in study group were significantly higher than those in control group(P<0.05);SCC-Ag,CEA,CYFRA21-1,IL-2,TNF-αand TGF-βlevels in both groups were decreased,which were lower in study group than control group(P<0.05);TCM symptom scores in both groups were decreased,which were lower in study group than control group(P<0.05),KPS and QoL scores were increased,which were higher in study group than control group(P<0.05);the incidence of adverse reactions in study group was lower than that in control group(P<0.05).Conclusion The curative effect of Shidachuan Mixture combined with chemotherapy is significant in patients with middle and advanced ESCC,which can effectively reduce levels of tumor markers and inflammatory factors,relieve TCM symptoms,improve behavioral ability and quality of life,and reduce the occurrence of adverse reactions.

关 键 词：食管鳞癌 中晚期 石打穿合剂 化疗 紫杉醇 顺铂 行为能力 

分 类 号：R273[医药卫生—中西医结合]